Select your country

AOK 11 tender round: STADA takes top active ingredients

  • 05/02/2013
  • Investor News

Awards for omeprazole, risperidone, simvastatin and mirtazapine, among others
Bad Vilbel, February 5, 2013

Following 18 awards in the tenth tender round of the Allgemeine Ortskrankenkasse (AOK) in the middle of January, Germany's largest association of statutory health insurance organizations has now once again selected STADA Group companies for six active ingredients in 38 alloted areas. In the process, STADA sales companies were awarded the four strongest active ingredients in terms of sales that were up for tender: omeprazole, risperidone, simvastatin and mirtazapine. These STADA products will now be available to the approximately 24 million individuals insured by AOK.


“The tendered active ingredients that STADA won are among the most commonly needed medicines in existence”, says Hartmut Retzlaff, Chairman of the Executive Board of STADA Arzneimittel AG. “We are happy that we can make a significant contribution to the supply of medicine and therefore to people's health as the only independent generics Group in Germany. In consideration of the challenging conditions of the German discount agreement system, that does not go without saying.”


The public health insurance association tendered a total of eight active ingredients each in eight alloted areas for three contract partners. STADApharm was awarded eight alloted areas for mirtazapine and omeprazole, five for risperidone, seven for simvastatin and one alloted area for the active ingredient combination of lisinopril and hydrochlorothiazide. ALIUD PHARMA was awarded eight areas for the active ingredient combination of losartan and hydrochlorothiazide as well as one alloted area for simvastatin. The contractual period starts on June 1, 2013.

About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA's business model focuses on the health care market. At the center of the internationally oriented business activities are the pharmaceutical and, in particular, the generics market with sustainable growth potentials. As a globally leading generics producer, STADA has a traditionally strong presence in Europe and is the clear number 3 in Germany. In financial year 2011, STADA achieved Group sales of EUR 1,715.4 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 337.2 million and adjusted net income of EUR 146.6 million. As of June 30, 2012, STADA employed 7,867 people worldwide.
For more information, please contact:


STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49 6101 603-165
Fax: +49 6101 603-506
e-mail: communications@stada.de